Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

Clinical trial NCT06500273 · RECRUITING

Trial details

NCT number: NCT06500273
Sponsor: Allogene Therapeutics
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Large B-cell Lymphoma

Start date: 2024-06-18
Primary completion: 2027-12-01
Enrollment: 250

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.